| Literature DB >> 34066462 |
Kanoknart Lantong1,2, Jirarat Songsri2, Sueptrakool Wisessombat2, Wanida Mala2, Warinda Prommachote2, Wilaiwan Senghoi2, Manas Kotepui3, Jedsada Kaewrakmuk4, Treenate Jiranantasak5, Apichai Tuanyok5, Wiyada Kwanhian Klangbud2.
Abstract
Burkholderia pseudomallei is a Gram-negative bacterium and the causative agent of melioidosis in humans and animals in the tropics. The clinical manifestations of melioidosis are diverse, ranging from localized infections to whole-body sepsis. The effective serological method is crucial for the point-of-care diagnosis of melioidosis. The aim of this study was to develop indirect immunofluorescence assay (IFA)-based methods for detecting immunoglobulin G (IgG) antibodies in melioidosis patients. These methods use whole-cell antigens made from recombinant E. coli strains that express major B. pseudomallei antigens, including TssM, OmpH, AhpC, BimA, and Hcp1. A total of 271 serum samples from culture-confirmed melioidosis patients (n = 81), patients with other known infections (n = 70), and healthy donors (n = 120) were tested. Our study showed that the recombinant TssM strain had the highest performance, with 92.6% sensitivity, 100% specificity, 100% positive predictive value, 96.9% negative predictive value, 97.8% efficiency, 97.0% accuracy, and no cross-reactivity. The method agreement analysis based on k efficiency calculations showed that all five IFA methods perfectly agreed with the standard culturing method, while the traditional indirect hemagglutination (IHA) method moderately agreed with the culture. In summary, our investigations showed that the TssM-IFA method could be used for melioidosis diagnosis.Entities:
Keywords: Burkholderia pseudomallei; Escherichia coli; TssM; immunofluorescence assay; melioidosis; whole-cell-based assay
Year: 2021 PMID: 34066462 PMCID: PMC8148196 DOI: 10.3390/pathogens10050559
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Whole cell-based indirect immunofluorescence assay (IFA) slides visualized under an immunofluorescence microscope for anti-B. pseudomallei antibody detection when tested and diluted 1:16 for a healthy donor (A,D,G), another known infection (Pseudomonas spp.) (B,E,H), and melioidosis (C,F,I) with E. coli-TssM indicating nonabsorbed, 1 h absorbed, and 2 h absorbed serum, respectively.
Figure 2Whole cell-based IFA slides for anti-B. pseudomallei antibody detection at a titer 1:16 for a melioidosis patient visualized under an immunofluorescence microscope: E. coli-TssM gene (A), E. coli-OmpH (B), E. coli-AhpC (C), E. coli-BimA (D), E. coli-Hcp1 (E), and CC-E. coli (cell control) (F).
Figure 3Whole cell-based IFA slides for anti-B. pseudomallei antibody detection at a titer of 1:16 for another known infection patient (A) and a healthy donor (B) visualized under an immunofluorescence microscope.
The area under curve (AUC) calculated from the relative operative cutoff (ROC) curve of different titer with different whole-cell-based IFA antigens.
| Titer | Area Under Curve (AUC) | ||||
|---|---|---|---|---|---|
| TssM | OmpH | AhpC | BimA | Hcp1 | |
| ≤1:8 | 0.958 | 0.918 | 0.908 | 0.895 | 0.804 |
| 1:16 | 0.963 | 0.942 | 0.929 | 0.910 | 0.811 |
| 1:32 | 0.963 | 0.942 | 0.929 | 0.910 | 0.811 |
| ≥1:64 | 0.963 | 0.942 | 0.929 | 0.910 | 0.811 |
Anti-B. pseudomallei antibody detection from different titers for all three sets of serum sample groups with different whole-cell-based IFA antigens.
| Serum Samples | Total No. | Number of Sample Positive with Antibody Titer | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TssM | OmpH | AhpC | BimA | Hcp1 | |||||||||||||||||
| 1:8 | 1:16 | 1:32 | 1:64 | 1:8 | 1:16 | 1:32 | 1:64 | 1:8 | 1:16 | 1:32 | 1:64 | 1:8 | 1:16 | 1:32 | 1:64 | 1:8 | 1:16 | 1:32 | 1:64 | ||
| Culture-confirmed melioidosis patients | 81 | 75 | 75 | 65 | 38 | 72 | 72 | 42 | 17 | 70 | 69 | 38 | 7 | 67 | 64 | 28 | 6 | 51 | 50 | 20 | 3 |
| Other known infections: | 70 | 2 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | 10 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 20 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
|
| 8 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hepatitis B virus (HBV) | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Human Immunodeficiency virus (HIV) | 11 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Healthy donors | 120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Anti-B. pseudomallei antibody detection by indirect hemagglutination assay (IHA) for different serum sources.
| Serum Samples | Total No. | Antibody Titer by IHA Assay | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤1:10 | 1:20 | 1:40 | 1:80 | 1:160 | 1:320 | 1:640 | 1:1280 | 1:2560 | ≥1:5120 | ||
| Culture-confirmed melioidosis patients | 81 | 39 | 4 | 4 | 3 | 8 | 11 | 5 | 3 | 1 | 2 |
| Other known infections: | 70 | 67 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 10 | 9 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 20 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hepatitis B virus (HBV) | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Human Immunodeficiency virus (HIV) | 11 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Healthy donors | 120 | 117 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Method performances and method agreement (k) of whole-cell-based IFA and IHA assays when the culture method is the reference method.
| Performances | IFA (Cut-Off ≥ 1:16) | IHA (Cut-Off ≥ 1:160) | ||||
|---|---|---|---|---|---|---|
| TssM | OmpH | AhpC | BimA | Hcp1 | ||
| Sensitivity (%) | 92.6 | 88.9 | 85.2 | 79.0 | 61.7 | 37.0 |
| Specificity (%) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 99.5 |
| PPV (%) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 69.77 |
| NPV (%) | 96.9 | 95.0 | 94.1 | 91.9 | 86.0 | 78.8 |
| Efficiency (%) | 97.8 | 96.7 | 95.5 | 93.7 | 88.6 | 80.8 |
| Accuracy (%) | 97.0 | 96.0 | 95.0 | 93.0 | 88.0 | 80.0 |
| Cross-reactivity (%) | 0 | 0 | 0 | 0 | 0 | 1.4 |
| Kappa coefficient ( | 0.95 | 0.91 | 0.88 | 0.84 | 0.80 | 0.41 |
A 2 × 2 contingency table illustrating the outcomes of a comparison between an alternative method (IFA or IHA) and the gold-standard culture method.
| Standard Culture Method | |||
|---|---|---|---|
| Positive | Negative | ||
|
|
| a | b |
|
| c | d | |
The strange of agreement is interpreted considering the kappa coefficient.
| Kappa Value ( | Strange of Agreement |
|---|---|
| <0.00 | Poor |
| 0.00–0.20 | Slight |
| 0.21–0.40 | Fair |
| 0.41–0.60 | Moderate |
| 0.61–0.80 | Substantial |
| 0.81–1.00 | Almost Perfect |